Literature DB >> 10549262

Allelotype of uterine leiomyomas.

X Mao1, R Barfoot, R A Hamoudi, D F Easton, A M Flanagan, M R Stratton.   

Abstract

Uterine leiomyomas are the most common benign tumor that arise from smooth muscle cells of the myometrium. Little is known about the etiology and pathogenesis of this tumor. To investigate the molecular pathogenesis of these tumors, we have conducted an allelotype of 102 leiomyomas from 12 patients, using 67 fluorescently-tagged oligonucleotide primers amplifying microsatellite loci covering all autosomes. No areas of the genome showed frequent loss of heterozygosity (LOH); however, the highest rate of LOH (9%) was observed on 7q, consistent with previous cytogenetic observations. Uterine leiomyomas are sometimes multiple. In general, multiplicity of other types of neoplasm is associated with genetic predisposition to the disease. Because multiple tumors were available from each of the 12 patients studied, we looked for evidence of allele-specific LOH, which might indicate the presence of an underlying predisposition gene. However, no evidence for allele-specific LOH was detected, indicating that if cases of multiple uterine leiomyoma are due to an underlying predisposition gene, it is unlikely to be a recessive oncogene.

Entities:  

Mesh:

Year:  1999        PMID: 10549262     DOI: 10.1016/s0165-4608(99)00053-9

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  9 in total

1.  Genome-wide analysis of loss of heterozygosity and copy number amplification in uterine leiomyomas using the 100K single nucleotide polymorphism array.

Authors:  Kellen L Meadows; Danica M K Andrews; Zongli Xu; Gleta K Carswell; Shannon K Laughlin; Donna D Baird; Jack A Taylor
Journal:  Exp Mol Pathol       Date:  2011-04-08       Impact factor: 3.362

2.  Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays.

Authors:  R Mei; P C Galipeau; C Prass; A Berno; G Ghandour; N Patil; R K Wolff; M S Chee; B J Reid; D J Lockhart
Journal:  Genome Res       Date:  2000-08       Impact factor: 9.043

Review 3.  Loss of heterozygosity analyzed by single nucleotide polymorphism array in cancer.

Authors:  Hai-Tao Zheng; Zhi-Hai Peng; Sheng Li; Lin He
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

4.  Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology.

Authors:  M Kiuru; V Launonen; M Hietala; K Aittomäki; O Vierimaa; R Salovaara; J Arola; E Pukkala; P Sistonen; R Herva; L A Aaltonen
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

5.  High polymorphism in the trisomic portion of a gastric cancer cell line.

Authors:  Blake A Jacobson; James M Fink; Bryan A Whitson; Lance J Ferrin
Journal:  J Gastroenterol       Date:  2007-03-30       Impact factor: 7.527

6.  High-resolution copy number analysis of paraffin-embedded archival tissue using SNP BeadArrays.

Authors:  Jan Oosting; Esther H Lips; Ronald van Eijk; Paul H C Eilers; Károly Szuhai; Cisca Wijmenga; Hans Morreau; Tom van Wezel
Journal:  Genome Res       Date:  2007-01-31       Impact factor: 9.043

7.  Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.

Authors:  Rainer Lehtonen; Maija Kiuru; Sakari Vanharanta; Jari Sjöberg; Leena-Maija Aaltonen; Kristiina Aittomäki; Johanna Arola; Ralf Butzow; Charis Eng; Kirsti Husgafvel-Pursiainen; Jorma Isola; Heikki Järvinen; Pasi Koivisto; Jukka-Pekka Mecklin; Päivi Peltomäki; Reijo Salovaara; Veli-Matti Wasenius; Auli Karhu; Virpi Launonen; Nina N Nupponen; Lauri A Aaltonen
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

8.  Integrated genomic analysis of sézary syndrome.

Authors:  Xin Mao; Tracy Chaplin; Bryan D Young
Journal:  Genet Res Int       Date:  2011-11-24

9.  Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas.

Authors:  K T Barker; S Bevan; R Wang; Y-J Lu; A M Flanagan; J A Bridge; C Fisher; C J Finlayson; J Shipley; R S Houlston
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.